Publications by authors named "Steven Caras"

Claim this Profile
P
Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect.
Steven Caras, Terrilyn Sharpe

J Child Adolesc Psychopharmacol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety.
Daniel E Falk, Megan L Ryan, Joanne B Fertig, Eric G Devine, Ricardo Cruz, Steven Caras

Alcohol Clin Exp Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Administration of CREON® pancrelipase pellets via gastrostomy tube is feasible with no loss of gastric resistance or lipase activity: an in vitro study.
George Shlieout, Andreas Koerner, Mario Maffert, Kristin Forssmann, Steven Caras

Clin Drug Investig· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency.
Robert J Kuhn, Andres Gelrud, Anne Munck, Steven Caras

Adv Ther· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial.
David C Whitcomb, Glen A Lehman, Galina Vasileva, Ewa Malecka-Panas, Natalya Gubergrits, Steven Caras

Am J Gastroenterol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study.
Gavin R Graff, John McNamara, James Royall, Steven Caras, Kristin Forssmann

Clin Drug Investig· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis.
Bruce C Trapnell, Karen Maguiness, Gavin R Graff, David Boyd, Katrin Beckmann, Steven Caras

J Cyst Fibros· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis